CIK 0001070081 · Large accelerated filer
PTC THERAPEUTICS, INC.
Sign in to watch- Ticker
- PTCT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043416587
- Phone
- 9082227000
- Business address
- 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059
- Former names
- PTC THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,752,145
- in 10 filings, $7.8M under 10b5-1 plans
Net −$7,752,145. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-02 | Golden Lee Scott EVP & CHIEF MEDICAL OFFICER | Grant or award · Stock Option (Right to Buy) | +46,875 | 46,875 | ||
| 2026-01-02 | Reeve Emma Director | Grant or award 10b5-1 | +4,000 | 10,666 | ||
| 2026-01-02 | Reeve Emma Director | Grant or award · Stock Option (Right to Buy) 10b5-1 | +3,475 | 3,475 | ||
| 2026-01-02 | Jacobson Allan Steven Director | Grant or award | +4,000 | 21,451 | ||
| 2026-01-02 | Jacobson Allan Steven Director | Grant or award · Stock Option (Right to Buy) | +3,475 | 3,475 | ||
| 2026-01-02 | Boulding Mark Elliott EXEC. VP AND CLO | Grant or award 10b5-1 | +17,000 | 120,901 | ||
| 2026-01-02 | Boulding Mark Elliott EXEC. VP AND CLO | Grant or award · Stock Option (Right to Buy) 10b5-1 | +42,500 | 42,500 | ||
| 2026-01-02 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Grant or award | +17,500 | 118,382 | ||
| 2026-01-02 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Grant or award | +520 | 6,956 | ||
| 2026-01-02 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Grant or award · Stock Option (Right to Buy) | +43,750 | 43,750 | ||
| 2026-01-02 | ZELDIS JEROME B Director | Grant or award | +4,000 | 22,500 | ||
| 2026-01-02 | ZELDIS JEROME B Director | Grant or award · Stock Option (Right to Buy) | +3,475 | 3,475 | ||
| 2026-01-02 | Pauwels Eric CHIEF BUSINESS OFFICER | Grant or award | +20,000 | 90,630 | ||
| 2026-01-02 | Pauwels Eric CHIEF BUSINESS OFFICER | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2026-01-02 | SCHMERTZLER MICHAEL Director | Grant or award | +8,000 | 163,266 | ||
| 2026-01-02 | SCHMERTZLER MICHAEL Director | Grant or award · Stock Option (Right to Buy) | +6,950 | 6,950 | ||
| 2026-01-02 | STEELE GLENN JR MD PHD Director | Option exercise 10b5-1 | +12,000 | $30.86 | $370K | 30,500 |
| 2026-01-02 | STEELE GLENN JR MD PHD Director | Sale 10b5-1 | −12,000 | $76.35 | $916K | 18,500 |
| 2026-01-02 | STEELE GLENN JR MD PHD Director | Grant or award 10b5-1 | +4,000 | 22,500 | ||
| 2026-01-02 | STEELE GLENN JR MD PHD Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,000 | 0 |
Page 13 of 25 · 493 trades